Literature DB >> 690251

Pharmacokinetics of prazosin in man.

D C Hobbs, T M Twomey, R F Palmer.   

Abstract

Prazosin was administered orally to 24 normotensive human subjects in the form of capsules or as a solution. Plasma concentrations indicate that drug is almost completely bioavailable from the capsules, although levels peak more slowly than from drug in solution. Drug leaves plasma with a half-life of approximately 2.3 hours. Examination of data from each subject on repeated dosing indicates considerable intrasubject consistency in pharmacokinetic response despite intersubject variability. The absence of the pharmacologically active metabolites in plasma suggests that the hypotensive response derives from drug only. Prazosin is bound to human plasma proteins to the extent of 97%.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 690251     DOI: 10.1002/j.1552-4604.1978.tb02456.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

1.  Comparative bioavailability study of two brands of prazosin-containing tablets in healthy volunteers.

Authors:  P J Guelen; T J Janssen; M H Lam; T B Vree; P S Exler
Journal:  Pharm Weekbl Sci       Date:  1990-10-19

2.  Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin.

Authors:  M G Scott; A H Deering; M T McMahon; D W Harron; R G Shanks
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure.

Authors:  N Lameire; J Gordts
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Pharmacokinetics of intravenous indoramin in middle-aged male and female volunteers.

Authors:  H M Norbury; R A Franklin; P K Marrott; S J Warrington
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Prazosin protein binding in health and disease.

Authors:  P Rubin; T Blaschke
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

6.  Pharmacokinetic and haemodynamic studies with prazosin in chronic heart failure.

Authors:  B Silke; S H Taylor
Journal:  Ir J Med Sci       Date:  1981-08       Impact factor: 1.568

7.  Pitfalls and valid approaches to pharmacokinetic analysis of mean concentration data following intravenous administration.

Authors:  D M Cocchetto; W A Wargin; J W Crow
Journal:  J Pharmacokinet Biopharm       Date:  1980-12

8.  Prazosin, pharmacokinetics and concentration effect.

Authors:  D N Bateman; D C Hobbs; T M Twomey; E A Stevens; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Variations in circulating catecholamines fail to alter human platelet alpha-2-adrenergic receptor number or affinity for [3H]yohimbine or [3H]dihydroergocryptine.

Authors:  M A Pfeifer; K Ward; T Malpass; J Stratton; J Halter; M Evans; H Beiter; L A Harker; D Porte
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

10.  Identification of a prazosin metabolite and some preliminary data on its kinetics in hypertensive patients.

Authors:  V K Piotrovskii; N N Veiko; O S Ryabokon; S F Postolnikov; V I Metelitsa
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.